These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver. Qiao C; Yuan Z; Li J; He B; Zheng H; Mayer C; Li J; Xiao X Gene Ther; 2011 Apr; 18(4):403-10. PubMed ID: 21150938 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression. Xie J; Xie Q; Zhang H; Ameres SL; Hung JH; Su Q; He R; Mu X; Seher Ahmed S; Park S; Kato H; Li C; Mueller C; Mello CC; Weng Z; Flotte TR; Zamore PD; Gao G Mol Ther; 2011 Mar; 19(3):526-35. PubMed ID: 21179009 [TBL] [Abstract][Full Text] [Related]
5. MicroRNA-restricted transgene expression in the retina. Karali M; Manfredi A; Puppo A; Marrocco E; Gargiulo A; Allocca M; Corte MD; Rossi S; Giunti M; Bacci ML; Simonelli F; Surace EM; Banfi S; Auricchio A PLoS One; 2011; 6(7):e22166. PubMed ID: 21818300 [TBL] [Abstract][Full Text] [Related]
6. Novel Combinatorial MicroRNA-Binding Sites in AAV Vectors Synergistically Diminish Antigen Presentation and Transgene Immunity for Efficient and Stable Transduction. Muhuri M; Zhan W; Maeda Y; Li J; Lotun A; Chen J; Sylvia K; Dasgupta I; Arjomandnejad M; Nixon T; Keeler AM; Manokaran S; He R; Su Q; Tai PWL; Gao G Front Immunol; 2021; 12():674242. PubMed ID: 33995418 [TBL] [Abstract][Full Text] [Related]
7. MicroRNA silencing improves the tumor specificity of adenoviral transgene expression. Card PB; Hogg RT; Gil Del Alcazar CR; Gerard RD Cancer Gene Ther; 2012 Jul; 19(7):451-9. PubMed ID: 22555510 [TBL] [Abstract][Full Text] [Related]
8. A double-switch vector system positively regulates transgene expression by endogenous microRNA expression (miR-ON vector). Amendola M; Giustacchini A; Gentner B; Naldini L Mol Ther; 2013 May; 21(5):934-46. PubMed ID: 23439497 [TBL] [Abstract][Full Text] [Related]
9. Single tyrosine mutation in AAV8 and AAV9 capsids is insufficient to enhance gene delivery to skeletal muscle and heart. Qiao C; Yuan Z; Li J; Tang R; Li J; Xiao X Hum Gene Ther Methods; 2012 Feb; 23(1):29-37. PubMed ID: 22428978 [TBL] [Abstract][Full Text] [Related]
10. Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Pulicherla N; Shen S; Yadav S; Debbink K; Govindasamy L; Agbandje-McKenna M; Asokan A Mol Ther; 2011 Jun; 19(6):1070-8. PubMed ID: 21364538 [TBL] [Abstract][Full Text] [Related]
11. One episode of low intensity aerobic exercise prior to systemic AAV9 administration augments transgene delivery to the heart and skeletal muscle. Pacak CA; Suzuki-Hatano S; Khadir F; Daugherty AL; Sriramvenugopal M; Gosiker BJ; Kang PB; Cade WT J Transl Med; 2023 Oct; 21(1):748. PubMed ID: 37875924 [TBL] [Abstract][Full Text] [Related]
12. Targeting transgene to the heart and liver with AAV9 by different promoters. Chen BD; He CH; Chen XC; Pan S; Liu F; Ma X; Li XM; Gai MT; Tao J; Ma YT; Yang YN; Gao XM Clin Exp Pharmacol Physiol; 2015 Oct; 42(10):1108-17. PubMed ID: 26173818 [TBL] [Abstract][Full Text] [Related]
13. Neonatal Systemic AAV-Mediated Gene Delivery of GDF11 Inhibits Skeletal Muscle Growth. Jin Q; Qiao C; Li J; Li J; Xiao X Mol Ther; 2018 Apr; 26(4):1109-1117. PubMed ID: 29503194 [TBL] [Abstract][Full Text] [Related]
14. Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated gene delivery. Majowicz A; Maczuga P; Kwikkers KL; van der Marel S; van Logtenstein R; Petry H; van Deventer SJ; Konstantinova P; Ferreira V J Gene Med; 2013; 15(6-7):219-32. PubMed ID: 23658149 [TBL] [Abstract][Full Text] [Related]
15. Local and systemic administration of AAV vectors with alphaherpesvirus latency-associated promoter 2 drives potent transgene expression in mouse liver, kidney, and skeletal muscle. Maturana CJ; Chan A; Verpeut JL; Engel EA J Virol Methods; 2023 Apr; 314():114688. PubMed ID: 36736702 [TBL] [Abstract][Full Text] [Related]
16. Long-term transgene expression in cardiac and skeletal muscle following fetal administration of adenoviral or adeno-associated viral vectors in mice. Bouchard S; MacKenzie TC; Radu AP; Hayashi S; Peranteau WH; Chirmule N; Flake AW J Gene Med; 2003 Nov; 5(11):941-50. PubMed ID: 14601131 [TBL] [Abstract][Full Text] [Related]
17. Effect of tissue-specific promoters and microRNA recognition elements on stability of transgene expression after hydrodynamic naked plasmid DNA delivery. Wolff LJ; Wolff JA; Sebestyén MG Hum Gene Ther; 2009 Apr; 20(4):374-88. PubMed ID: 19199823 [TBL] [Abstract][Full Text] [Related]
18. Comparison of adeno-associated virus serotypes and delivery methods for cardiac gene transfer. Fang H; Lai NC; Gao MH; Miyanohara A; Roth DM; Tang T; Hammond HK Hum Gene Ther Methods; 2012 Aug; 23(4):234-41. PubMed ID: 22966786 [TBL] [Abstract][Full Text] [Related]
19. Conditional Regulation of Gene Expression by Ligand-Induced Occlusion of a MicroRNA Target Sequence. Mou H; Zhong G; Gardner MR; Wang H; Wang YW; Cheng D; Farzan M Mol Ther; 2018 May; 26(5):1277-1286. PubMed ID: 29567311 [TBL] [Abstract][Full Text] [Related]
20. Systemic and Persistent Muscle Gene Expression in Rhesus Monkeys with a Liver De-Targeted Adeno-Associated Virus Vector. Tarantal AF; Lee CCI; Martinez ML; Asokan A; Samulski RJ Hum Gene Ther; 2017 May; 28(5):385-391. PubMed ID: 28125921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]